Menu

Markets

Research

News

Learn
Paper trading
AI Chat
Get the app WatchlistsPortfoliosAlerts
Sign in

Atara Biotherapeutics, Inc. ATRA

Set alert

Price alert · ATRA

All alert types
8.48 USD +0.47 +5.87%

At close · Nov 2

8.48 0.00 0.00%

After hours · Nov 2, 4:00 PM ET

Bid
8.41 × 1
Ask
8.49 × 1
8.02 Day range 8.59
3.92 52-week range 19.15
YTD
-53.12%
1 year
-42.90%
Open
8.05
Prev close
8.01
Mkt cap
85.12M
Vol
32.05K
Avg vol
41.18K
EPS
-1.30
P/E
0.00
Div yield
0.00%
More statistics
Low
8.02
High
8.59
Forward P/E
-1.52
Beta
0.49
Short ratio
7.11
Inst. own
50.82%
Dividend
0.00
Ex-div date
50-d avg
10.80
200-d avg
11.70
1y target
16.33

6M chart

Chart tools
Interval
1m5m15m30m

Signals (35)
NameDateAgo
SMA: BearishOct 23, 20261 week ago
SMA: BearishOct 23, 20261 week ago
MACD: Sell SignalOct 23, 20261 week ago
SMA: BullishOct 21, 20261 week ago
SMA: BullishOct 21, 20261 week ago
MACD: Buy SignalOct 21, 20261 week ago
MACD: Sell SignalOct 20, 20261 week ago
SMA: BearishOct 16, 20262 weeks ago
SMA: BearishOct 16, 20262 weeks ago
SMA: BullishOct 14, 20262 weeks ago
SMA: BearishOct 12, 20263 weeks ago
SMA: BullishOct 9, 20263 weeks ago
SMA: BearishOct 7, 20263 weeks ago
SMA: BullishOct 6, 20263 weeks ago
SMA: BearishOct 5, 20264 weeks ago
MACD: Buy SignalOct 5, 20264 weeks ago
SMA: BullishOct 2, 20261 month ago
SMA: BullishOct 2, 20261 month ago
SMA: BearishSep 22, 20261 month ago
MACD: Sell SignalSep 18, 20261 month ago

Newest 20 of 35.

Analyst view

Consensus: buy

Buy
Price target (mean) 16.33 +92.6% upside
Target (low)
10.00
Target (mean)
16.33
Target (high)
21.00
Ratings (0m) 6 3 buy · 3 hold · 0 sell
  • Strong buy0
  • Buy3
  • Hold3
  • Sell0
  • Strong sell0

Recommendation trend

  • This month 6
  • 1 month ago 7

Earnings and revenue estimates

Consensus for the coming quarters and fiscal years

ATRA analyst estimates
PeriodEPS estimateLow – highYear agoEPS growthRevenue estimateRevenue growthAnalysts
Current quarter-2.34-2.49 – -2.18-14.00+83.3%33.09M+678.3%2
Next quarter-0.16-3.37 – 3.05-5.75+97.2%37.35M+36.5%2
Current year-1.52-2.23 – -0.80-65.25+97.7%129.19M+1406.9%2
Next year-11.96-20.49 – -0.97-1.52-689.6%84.82M-34.3%4

Upgrades and downgrades

The latest rating changes

ATRA analyst upgrades and downgrades
DateFirmActionFromTo
Dec 20, 2024Rodman & RenshawInitiated—Buy
Nov 13, 2024Canaccord GenuityMaintainedBuyBuy
Aug 21, 2024HC Wainwright & Co.Reiterated—Neutral
Aug 16, 2024MizuhoUpgradeNeutralOutperform
Aug 13, 2024Canaccord GenuityMaintainedBuyBuy
Jul 17, 2024Goldman SachsMaintainedSellSell
May 22, 2024HC Wainwright & Co.Reiterated—Neutral
Apr 1, 2024StifelMaintainedHoldHold
Nov 10, 2023Goldman SachsMaintainedSellSell
Nov 9, 2023Evercore ISI GroupDowngradeOutperformIn-Line
Nov 9, 2023HC Wainwright & Co.DowngradeBuyNeutral
Nov 9, 2023MizuhoDowngradeBuyNeutral
Sep 26, 2023HC Wainwright & Co.ReiteratedBuyBuy
Aug 21, 2023CitigroupMaintainedSellSell
Aug 9, 2023EF HuttonReiteratedBuyBuy
Jun 14, 2023HC Wainwright & Co.MaintainedBuyBuy
May 9, 2023Canaccord GenuityMaintained—Buy
Feb 9, 2023EF HuttonReiterated—Buy
Feb 9, 2023HC Wainwright & Co.Maintained—Buy
Feb 7, 2023MizuhoReiterated—Buy
Jan 5, 2023EF HuttonInitiated—Buy
Aug 16, 2022MizuhoMaintained—Buy
Aug 9, 2022Goldman SachsMaintained—Sell
Jul 20, 2022CitigroupDowngradeNeutralSell
Jul 13, 2022JP MorganDowngradeOverweightNeutral
Jul 13, 2022StifelDowngradeBuyHold
May 24, 2022Goldman SachsMaintained—Sell
May 23, 2022HC Wainwright & Co.Maintained—Buy
May 10, 2022CitigroupDowngradeBuyNeutral
Mar 28, 2022JP MorganMaintained—Overweight